Atif Ali Hashmi

8PUBLICATIONS
41CO-AUTHORS
Molecular targetsClinical midwiferyMedical mycologyCancer diagnosisPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Sep 09, 2026
ERBB2 Activating Mutations Promote Enhanced Internalization and Activity of Trastuzumab Deruxtecan in HER2-non-amplified Metastatic Breast Cancer.

|Nov 10, 2025
Trastuzumab Deruxtecan Resistance via Loss of HER2 Expression and Binding.

Wanyi Chen, Avantika Gupta, Nicholas Mai

|Oct 09, 2025
Programmed Death Ligand 1 (PDL1) Expression in Neoadjuvant Triple-Negative Breast Cancer: Association With Chemotherapy Response and Residual Cancer Burden.

Atif Ali Hashmi, Noreen Wahid, Ghazala Mudassir

|Apr 29, 2025
Clinicopathological features of microinvasive lobular carcinoma.

Rachel Han, Atif A Hashmi, Hannah Y Wen

|Feb 26, 2025
Predictive Value of Excision Repair Cross Complementation Group 1 (ERCC1) by Immunohistochemistry for Determining Neoadjuvant Chemotherapy Response in Triple-Negative Breast Cancers.

Atif Ali Hashmi, Yumna Ajaz, Muhsana Sajjad

|Sep 05, 2024
Risk Factors of Oral Squamous Cell Carcinoma with Special Emphasis on Areca Nut Usage and Its Association with Clinicopathological Parameters and Recurrence.

Atif Ali Hashmi, Ghazala Mudassir, Khushbakht Rashid

Pageof 2

Frequent Collaborators

4 joint publications

Muhammad Irfan

3 joint publications

Fazail Zia

3 joint publications

Umair Arshad Malik

2 joint publications

Fresia Pareja